Johnson & Johnson (NYSE:JNJ) Stock Holdings Increased by Naviter Wealth LLC

Naviter Wealth LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 43.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,281 shares of the company’s stock after buying an additional 6,174 shares during the period. Naviter Wealth LLC’s holdings in Johnson & Johnson were worth $3,208,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $4,071,642,000. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 16.4% in the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after acquiring an additional 3,391,657 shares during the last quarter. International Assets Investment Management LLC grew its holdings in shares of Johnson & Johnson by 7,875.8% in the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock worth $327,647,000 after acquiring an additional 2,064,175 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth $193,050,000. Finally, Global Assets Advisory LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter worth $170,372,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Morgan Stanley decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Bank of America lowered their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $145.62 on Thursday. The business’s 50-day moving average price is $148.02 and its two-hundred day moving average price is $153.91. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company has a market capitalization of $350.46 billion, a P/E ratio of 9.08, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the previous year, the company posted $2.68 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.